Regulus Therapeutics
RGLS
#8770
Rank
S$0.12 B
Marketcap
$1.95
Share price
-0.68%
Change (1 day)
8.71%
Change (1 year)

P/E ratio for Regulus Therapeutics (RGLS)

P/E ratio as of November 2024 (TTM): -0.8698

According to Regulus Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.869823. At the end of 2022 the company had a P/E ratio of -0.7366.

P/E ratio history for Regulus Therapeutics from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.7366-24.73%
2021-0.9786-60.13%
2020-2.45203.37%
2019-0.8091387.19%
2018-0.1661-82.34%
2017-0.9405-35.21%
2016-1.45-81.85%
2015-8.00-36.16%
2014-12.5-15.21%
2013-14.89286.92%
2012-0.1575

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.4-1,291.78%๐Ÿ‡ฌ๐Ÿ‡ง UK
16.1-1,955.22%๐Ÿ‡ซ๐Ÿ‡ท France
9.37-1,177.67%๐Ÿ‡บ๐Ÿ‡ธ USA
32.5-3,835.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
-67.5 7,660.34%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.99 129.13%๐Ÿ‡บ๐Ÿ‡ธ USA
13.6-1,667.82%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.